FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 153 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple... August 8, 2025 FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens... January 9, 2023 Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas March 12, 2024 Cervical screening in Wales extended to every 5 years: Why the... January 7, 2022 Load more HOT NEWS Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling... Hormone therapy gets green light for advanced prostate cancer Four randomized prospective degree compared 90 days regarding neoadjuvant ADT observed... Transforming Cancer Clinical Trials for Better, Faster Results
